{"name":"French Innovative Leukemia Organisation","slug":"french-innovative-leukemia-organisation","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":7,"colorKey":"oncology","drugs":[{"name":"CEEP regimen","genericName":"CEEP regimen","slug":"ceep-regimen","indication":"Acute lymphoblastic leukemia","status":"phase_2"},{"name":"Lomustine, intermediate dose cytarabine","genericName":"Lomustine, intermediate dose cytarabine","slug":"lomustine-intermediate-dose-cytarabine","indication":"Acute leukemia (likely acute myeloid leukemia or acute lymphoblastic leukemia)","status":"phase_3"},{"name":"Cytarabine-Venetoclax Association","genericName":"Cytarabine-Venetoclax Association","slug":"cytarabine-venetoclax-association","indication":"Acute Myeloid Leukemia (AML) in adults who are ineligible for intensive chemotherapy","status":"phase_2"},{"name":"Experimental (fludarabine)","genericName":"Experimental (fludarabine)","slug":"experimental-fludarabine","indication":"Chronic lymphocytic leukemia (CLL)","status":"phase_3"},{"name":"MINI CHEP","genericName":"MINI CHEP","slug":"mini-chep","indication":"Acute leukemia (elderly or unfit patients)","status":"phase_3"},{"name":"Xospata","genericName":"Xospata","slug":"xospata","indication":"Acute myeloid leukemia, disease","status":"marketed"},{"name":"alkeran","genericName":"alkeran","slug":"alkeran","indication":"Malignant tumor of ovary","status":"phase_2"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"immunology","drugs":[{"name":"Ruxolotinib","genericName":"Ruxolotinib","slug":"ruxolotinib","indication":"Other","status":"phase_2"},{"name":"ACA Continuation","genericName":"ACA Continuation","slug":"aca-continuation","indication":"Continuation of ACA treatment","status":"phase_2"},{"name":"Adriblastin","genericName":"Adriblastin","slug":"adriblastin","indication":"Other","status":"phase_2"},{"name":"First line therapy","genericName":"First line therapy","slug":"first-line-therapy","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"CEEP regimen","genericName":"CEEP regimen","slug":"ceep-regimen","phase":"phase_2","mechanism":"CEEP regimen is a combination of chemotherapy drugs used to treat acute lymphoblastic leukemia.","indications":["Acute lymphoblastic leukemia"],"catalyst":""},{"name":"Lomustine, intermediate dose cytarabine","genericName":"Lomustine, intermediate dose cytarabine","slug":"lomustine-intermediate-dose-cytarabine","phase":"phase_3","mechanism":"This combination uses lomustine (a nitrosourea alkylating agent) and intermediate-dose cytarabine (a nucleoside antimetabolite) to damage cancer cell DNA and inhibit DNA synthesis.","indications":["Acute leukemia (likely acute myeloid leukemia or acute lymphoblastic leukemia)"],"catalyst":""},{"name":"Ruxolotinib","genericName":"Ruxolotinib","slug":"ruxolotinib","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ACA Continuation","genericName":"ACA Continuation","slug":"aca-continuation","phase":"phase_2","mechanism":"ACA Continuation works by continuing the effects of ACA.","indications":["Continuation of ACA treatment"],"catalyst":""},{"name":"Adriblastin","genericName":"Adriblastin","slug":"adriblastin","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Cytarabine-Venetoclax Association","genericName":"Cytarabine-Venetoclax Association","slug":"cytarabine-venetoclax-association","phase":"phase_2","mechanism":"Cytarabine-Venetoclax Association works by combining cytarabine's DNA synthesis inhibition with venetoclax's selective inhibition of BCL-2 protein, leading to enhanced apoptosis in leukemia cells.","indications":["Acute Myeloid Leukemia (AML) in adults who are ineligible for intensive chemotherapy"],"catalyst":""},{"name":"Experimental (fludarabine)","genericName":"Experimental (fludarabine)","slug":"experimental-fludarabine","phase":"phase_3","mechanism":"Fludarabine is a purine analog that inhibits ribonucleotide reductase and DNA polymerase, leading to DNA strand breaks and apoptosis in rapidly dividing cells.","indications":["Chronic lymphocytic leukemia (CLL)","Acute leukemia","Lymphoma"],"catalyst":""},{"name":"First line therapy","genericName":"First line therapy","slug":"first-line-therapy","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"MINI CHEP","genericName":"MINI CHEP","slug":"mini-chep","phase":"phase_3","mechanism":"MINI CHEP is a chemotherapy regimen combining mini-dose chemotherapy agents designed to treat acute leukemia with reduced toxicity.","indications":["Acute leukemia (elderly or unfit patients)"],"catalyst":""},{"name":"Xospata","genericName":"Xospata","slug":"xospata","phase":"marketed","mechanism":"ADP/ATP translocase 2, ADP/ATP translocase 3, Bone morphogenetic protein receptor type-1B","indications":["Acute myeloid leukemia, disease"],"catalyst":""},{"name":"alkeran","genericName":"alkeran","slug":"alkeran","phase":"phase_2","mechanism":"L-type amino acid transporter 1","indications":["Malignant tumor of ovary","Multiple myeloma"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":11,"phaseCounts":{"phase_2":7,"phase_3":3,"marketed":1},"enrichmentLevel":0,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}